Analysis of circulating tumor DNA (ctDNA) is emerging as a powerful tool for guiding targeted therapy and monitoring tumor evolution in patients with non-small cell lung cancer (NSCLC), especially when representative tissue biopsies are not available. Here, we have compared the ability of four leading technology platforms to detect epidermal growth factor receptor (EGFR) mutations (L858R, exon 19 deletion, T790M and G719X) in ctDNA from NSCLC patients. Two amplification refractory mutation systems (cobas-ARMS and ADx-ARMS), a droplet digital polymerase chain reaction (ddPCR) and a next-generation sequencing (Firefly NGS) platform were included in the comparison. Fifteen EGFR mutations across twenty NSCLC patients were identified. Firefly NG...
<p><strong>Background: </strong>Specific mutations in epidermal growth factor receptor (<em>EGFR</em...
Purpose: We aimed to investigate the feasibility of droplet digital PCR (ddPCR) for the quantitative...
Over the past years, targeted therapies using tyrosine kinase inhibitors (TKI) have led to an increa...
AbstractObjectivesTo assess the ability of different technology platforms to detect epidermal growth...
Lung cancer is the leading cause of cancer-related mortality worldwide. Epidermal growth factor rece...
The advances in targeted therapies for lung cancer are based on the evaluation of specific gene muta...
BACKGROUND: Liquid biopsy is emerging as an important approach for tumor genotyping in non-small cel...
Molecular evaluation of EGFR mutation is indispensable in treating non-small cell lung cancer (NSCLC...
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Epideral growth factor re...
Background: Mutations in the epidermal growth factor receptor gene, EGFR, predict response or resist...
Introduction:Detection of epidermal growth factor receptor (EGFR) mutations is indispensable to dete...
PURPOSE To compare the results of plasma cell-free DNA (cfDNA) droplet digital PCR (ddPCR) and next-...
<div><p>Background</p><p>Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive epid...
PURPOSE: We studied EGFR mutations in circulating tumor DNA (ctDNA) and explored their role in predi...
Background Analysis of cell-free DNA from blood could provide an alternative method for identifying ...
<p><strong>Background: </strong>Specific mutations in epidermal growth factor receptor (<em>EGFR</em...
Purpose: We aimed to investigate the feasibility of droplet digital PCR (ddPCR) for the quantitative...
Over the past years, targeted therapies using tyrosine kinase inhibitors (TKI) have led to an increa...
AbstractObjectivesTo assess the ability of different technology platforms to detect epidermal growth...
Lung cancer is the leading cause of cancer-related mortality worldwide. Epidermal growth factor rece...
The advances in targeted therapies for lung cancer are based on the evaluation of specific gene muta...
BACKGROUND: Liquid biopsy is emerging as an important approach for tumor genotyping in non-small cel...
Molecular evaluation of EGFR mutation is indispensable in treating non-small cell lung cancer (NSCLC...
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Epideral growth factor re...
Background: Mutations in the epidermal growth factor receptor gene, EGFR, predict response or resist...
Introduction:Detection of epidermal growth factor receptor (EGFR) mutations is indispensable to dete...
PURPOSE To compare the results of plasma cell-free DNA (cfDNA) droplet digital PCR (ddPCR) and next-...
<div><p>Background</p><p>Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive epid...
PURPOSE: We studied EGFR mutations in circulating tumor DNA (ctDNA) and explored their role in predi...
Background Analysis of cell-free DNA from blood could provide an alternative method for identifying ...
<p><strong>Background: </strong>Specific mutations in epidermal growth factor receptor (<em>EGFR</em...
Purpose: We aimed to investigate the feasibility of droplet digital PCR (ddPCR) for the quantitative...
Over the past years, targeted therapies using tyrosine kinase inhibitors (TKI) have led to an increa...